Roivant Sciences Ltd Dossier - Source-backed chat

Roivant Sciences Ltd

ROIVNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.09

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $35.50Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $25.6B

Enterprise Value $24.7B

Shares Outstanding 734.4M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

FDA approval and immediate U.S. availability of LISRAYA materially de-risked Roivant's lead program and created a commercial foundation for brepocitinib. The remaining investment outcome is still highly dependent on launch execution and several binary clinical events: Phase 3 non-infectious-uveitis data, IMVT-1402 cutaneous-lupus data, and mosliciguat PH-ILD data are expected in the second half of 2026, while brepocitinib is also in registrational development for cutaneous sarcoidosis and lichen planopilaris. The balance between a newly approved product and substantial unresolved clinical uncertainty supports a Hold rather than a more directional recommendation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$37.00

Mean target$41.82

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$37.0025%

LISRAYA uptake falls short of expectations because of access friction, competition from established treatment patterns, or concern regarding the boxed safety warning. One or more major 2026 trials fail or are delayed, weakening the multi-asset narrative and concentrating value in a single newly launched rare-disease indication. Slower BEACON+ enrollment would further defer potential indication expansion.

Base CaseCentral scenario

$41.8257%

Matches the consensus mean

LISRAYA adoption develops gradually because a rare-disease launch requires specialist education, payer access, and safety monitoring. The late-2026 readouts are mixed rather than uniformly positive, leaving one or more credible follow-on programs but preserving substantial development risk.

Bull CaseUpside scenario

$50.0018%

LISRAYA achieves strong specialist adoption, access broadens without a material safety-related impediment, and the principal 2026 clinical readouts are positive. Successful non-infectious-uveitis data would strengthen the brepocitinib franchise, while positive IMVT-1402 and mosliciguat results would demonstrate that value creation extends beyond one medicine. Continued progress in cutaneous sarcoidosis and lichen planopilaris would add further indication-expansion optionality.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

LISRAYA became immediately available in the United States after FDA approval in August 2026 and is the first targeted therapy approved for adults with dermatomyositis.
Brepocitinib has additional registrational programs in non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris, creating multiple opportunities to extend the franchise.
Roivant's current pipeline also includes registrational IMVT-1402 programs across several autoimmune indications and proof-of-concept development of mosliciguat in PH-ILD.

Key Investment Risks

LISRAYA carries a boxed warning covering serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, which may influence prescribing and monitoring.
The investment case remains exposed to binary clinical outcomes from brepocitinib, IMVT-1402, and mosliciguat studies expected during the second half of 2026.
Most proposed indication expansion remains unapproved, and registrational status does not ensure successful enrollment, positive results, regulatory approval, or commercialization.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.